By San José, Costa Rica — San José, Costa Rica – The Costa Rican Social Security Fund (CCSS) has announced a significant strategic enhancement to its healthcare budget, earmarking ₡6.335 billion for the treatment of multiple sclerosis (MS) in 2026. This figure represents a substantial increase of nearly ₡814 million over the previous year, signaling a decisive move to broaden patient access to the most advanced and effective therapies available on the market.
This considerable financial injection is primarily driven by the institution’s commitment to incorporating and expanding the use of high-efficacy biologic therapies. These cutting-edge treatments are specifically designed to manage the more aggressive recurrent and progressive forms of the neurological disease, offering new hope to patients facing the most challenging prognoses. The move reflects a broader trend in modern healthcare, prioritizing targeted, high-impact medications to alter disease progression rather than merely managing symptoms.
To understand the legal framework governing patient access to innovative medical treatments, TicosLand.com consulted with Lic. Larry Hans Arroyo Vargas, an expert attorney from the prominent firm Bufete de Costa Rica, who sheds light on the rights and obligations within our healthcare system.
The approval of new therapies for Multiple Sclerosis is not just a medical breakthrough; it is a legal trigger for the State’s duty to protect the right to health. In Costa Rica, patients have a strong legal basis, often enforced through the Constitutional Court, to demand that the CCSS provide access to proven, effective treatments, even if they are high-cost. The legal precedent prioritizes the right to life and health over budgetary limitations, ensuring that medical innovation translates into tangible patient care.
Lic. Larry Hans Arroyo Vargas, Attorney at Law, Bufete de Costa Rica
This legal perspective is indeed crucial, reminding us that the bridge between medical innovation and patient access is built upon the foundation of fundamental rights. We sincerely thank Lic. Larry Hans Arroyo Vargas for his invaluable insight, which underscores how Costa Rica’s legal framework ensures that breakthroughs in treatment become a tangible reality for those in need.
At the forefront of this expansion is ocrelizumab, one of the most advanced treatments for MS. The CCSS projects a major increase in the number of patients receiving this therapy, growing from 207 individuals in 2025 to 330 in the coming year. A significant portion of the budget increase, an estimated ₡295 million, is allocated to facilitate this specific expansion, underscoring the drug’s importance in the national treatment strategy. This investment aims to provide a more robust defense against the debilitating effects of the disease for a larger patient cohort.
In addition to ocrelizumab, the public health authority will also increase access to another specialized biologic, ofatumumab. The number of patients prescribed this medication is set to rise from 83 to 100. While a more modest increase, it further diversifies the therapeutic options available within the public system, allowing physicians to tailor treatments more precisely to individual patient needs and disease profiles.
Multiple sclerosis is a chronic and often disabling autoimmune disease that attacks the central nervous system, including the brain and spinal cord. It can lead to a wide range of severe symptoms, such as profound difficulties with mobility, vision problems, cognitive impairment, and ultimately, progressive long-term disability. The most prevalent form of the condition is relapsing-remitting MS, which accounts for approximately 85% of all diagnosed cases in the country.
The challenge for any healthcare system is managing a condition that currently has no cure. However, the CCSS is focusing its resources on what is possible: mitigating the disease’s impact. Officials emphasize that modern treatments can significantly alter its course, reduce the frequency and severity of relapses, and substantially delay the onset of permanent disability.
While it has no cure, treatments do exist that can modify the course of the disease, reduce relapses, and delay disability.
CCSS Authorities
The primary hurdle in this endeavor is ensuring the sustained availability of these therapies, which are characterized by their high cost and the necessity for continuous, specialized medical supervision. With this new investment, the CCSS is directly confronting this challenge. The institution’s overarching goals are to fortify timely and equitable access to these life-changing medications and, in doing so, tangibly improve the daily quality of life and long-term outlook for all Costa Ricans living with multiple sclerosis.
For further information, visit ccss.sa.cr
About Caja Costarricense de Seguro Social (CCSS):
The Caja Costarricense de Seguro Social is the cornerstone of Costa Rica’s public health system. As an autonomous government institution, it is responsible for providing comprehensive healthcare and managing the nation’s pension system. Founded on the principles of universality, solidarity, and equity, the CCSS ensures that nearly all residents have access to medical services, from primary care to complex surgical procedures, regardless of their ability to pay.
For further information, visit bufetedecostarica.com
About Bufete de Costa Rica:
As a cornerstone of Costa Rica’s legal landscape, Bufete de Costa Rica is defined by its unwavering ethical principles and a distinguished standard of excellence. The firm leverages its extensive experience across numerous industries to pioneer innovative legal strategies and solutions. Central to its philosophy is a profound dedication to societal advancement, actively working to democratize legal knowledge and thereby empower citizens to create a more equitable and well-informed community.
